Fluid Biomarker Changes After Amyloid-β–Targeting Drugs
Recent scientific advancements in the field of Alzheimer disease (AD) have led to numerous questions and challenges. On the one hand, with the emergence of robust methodologies for measuring in vivo brain changes in biofluids, like cerebrospinal fluid (CSF) and plasma, accurate detection of the…